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Abstract
Background: Hyperlipidemia and oxidative stress are major risk factors for atherosclerosis, and all three are among
the most important risk factors for cardiovascular diseases. Cassia occidentalis aqueous extract has been used in
African traditional medicine for the treatment of hypertension and associated cardiovascular diseases. This study
was undertaken to evaluate the hypolipidemic and anti-atherosclerotic properties of the aqueous extract of the
leaves of C. occidentalis in rats with hypercholesterolemia (HC).
Sixty Normocholesterolemic (NC) male rats were divided into six groups (n = 10) and fed a high-cholesterol (HC)
diet for 30 days (5 groups), or normal rat chow (normal control group). The plant extract was administered to
animals at the increasing dose of 240, 320 and 400 mg/kg. After 4 weeks of treatment 5 rats out of 10 were
sacrificed, blood samples, aorta, liver, and fresh faecal were collected and processed for biochemical tests. The
experiments were conducted under the same conditions with a group of rat treated with Atorvastatin (1 mg/kg),
used positive control. The effects of C. occidentalis on weight gain, water and food consumptions, levels of serum
lipids and lipoprotein lipid oxidation and stress markers in blood and liver were also examined.
Results: A significant body weight gain was observed in general in all the group of animals without any treatment
after 4 weeks. During the treatment period, the C. occidentalis extract induced a significant increase (P < 0.01) in
water consumption and food intakes. After 4 weeks of treatment with hypercholesterolemia, the body temperature
and organ weights including the liver, kidney, heart and the testis did not present any significant change. The
administration of C. occidentalis extract significantly (p < 0.05) prevented the elevation in TC, LDL-C, VLDL-C, hepatic
and aortic TG and TC. The atherogenic, triglycerides, and lipid peroxidation (TBARS) index were also decreased in
the rats treated with the plant extract. C. occidentalis favoured the performance of faecal cholesterol. It also
significantly inhibited the changes and the formation of aortic atherosclerotic plaques.
Conclusion: This study provides evidence of hypolipidemic and antiatherosclerotic effects of C. occidentalis extract.
C. occidenntalis aqueous extract reduced bad cholesterols, triglycerides and increasing good cholesterols in rats
subjected to a feeding regime enriched with cholesterol. The results support the traditional use of the extract of
this plant in the treatment of hypertension and diabetes.
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Background
Hyperlipidemia and oxidative stress are major risk fac-
tors for atherosclerosis, and all three are among the
most important risk factors for cardiovascular diseases
and conditions [1, 2]. The cardiovascular diseases con-
stitute one of the absolutely largest public health prob-
lem in the world. According to the World Health
Organization statistics [3], they are responsible of more
than 17 million deaths annually. The cardiovascular
diseases are associated to several cardio-metabolic risk
factors such as hypercholesterolemia, diabetes, high
blood pressure, obesity and sedentarity [4]. Dyslipidemia
is a very frequent metabolic disorder which is character-
ized by an increase of the rates of triglycerides (TG),
total cholesterol (CT), cholesterol of the low density
lipoprotein (LDL-c) and a reduction of the cholesterol
high density lipoprotein (HDL-c) [4]. A huge body of
population based and experimental evidence shows that
high levels of plasma low density lipoprotein (LDL-c)
cholesterol and total cholesterol considerably increase
the risk for developing atherosclerosis and associated
arterial hypertension [5, 6]. Other changes in lipid
parameters associated with atherosclerosis include de-
creases in high density lipoprotein (HDL-c) cholesterol
and increases in triglycerides. It is well documented that
hypercholesterolemia contributes to the development
of the atherosclerosis, with hypertension and the renal
failure [7]. The assumption of responsibility of the
hypercholesterolemia in reduction of mortality as well
as which has occurred of the events cardio/neurovascu-
laires, this via the reduction in the blood concentration
of cholesterol related to the lipoproteins of low density
(LDL-c). The low-density lipoprotein cholesterol (LDL-c)
reduction is correlated with the magnitude of cardiovascu-
lar risks reduction.
For many decades medicinal plants have been used to
prevent or treat various diseases. They are used through-
out the world, for their hypoglycemia, hypolipidemia or
antioxidant activities [8, 9]. Cassia occidentalis Linn.
(Caesalpiniaceae) is a diffuse shrub (usually annual),
with loosely spreading branches (60–150 cm long), and
can grow up to an altitude of 1500 m [10]. Different
parts of this plant have been reported to possess anti-
inflammatory, antihepatotoxic [11], antibacterial [12],
antiplasmodial [13] and antidiabetic [14] activities.
They possess purgative, tonic, febrifugal, expectorant,
and diuretic properties. The plant is also used to cure
sore eyes, hematuria, rheumatism, typhoid, asthma,
hemoglobin disorders and it is also reported to cure
leprosy. A wide range of chemical constituents isolated
from C. occidentalis include sennoside, anthraquinone
glycoside [15], fatty oils, flavonoid glycosides, galacto-
mannan, polysaccharides, and tannins [16]. Although
leaves aqueous extract of C. occidentalis were reported
to possess diuretic effects [17], no data on the effect of
this medicinal plant on cardiovascular diseases and
conditions are available. The present study therefore
aimed at evaluating the anti-dyslipidemic, antioxidant,
and anti-atherogenic effects of C. occidentalis leaf aqueous
extracts and potential mechanisms driving its putative
protective and therapeutic effects.
Methods
Plant material
Fresh leaves of C. occidentalis used in this study were
harvested in Mora 60 Km from Maroua, the largest city
in the Far North Region, Cameroon in July 2013. They
were identified by experts of the National Herbarium
of Cameroon and a sample was deposited (specimen
N0 21057/SFR/CAM). Leaves of C. occidentalis were
extracted as described previously [17].
Preparation of leave aqueous extract
Fresh leaves of C. occidentalis were soaked in distilled
water (1000 g for 1 L at room temperature) for 12 h.
The macerate was filtered through Whatman filter paper
No 3, and the filtrate concentrated in a rotary evaporator
at 40 °C for 24 h. This process was repeated until an oily
paste extract was obtained (130 g), which represented
the concentrated crude extract of C. occidentalis leaves.
The extract was stored at −20 °C until use. The solution
of C. occidentalis extract with the highest concentration
tested was prepared by dissolving 800 mg of the con-
centrated crude extract obtained previously in 10 ml of
distilled water (80 mg/mL concentration). The other
solutions used in the study were 4:5, 3:5, 2:5, and 1:5
dilutions of this solution in distilled water. Solutions
were given per os in a volume of 5 ml/kg body weight,
thus, the increasing doses of aqueous extract of C. occi-
dentalis tested were 80, 160, 240, 320, and 400 mg/kg.
Preliminary qualitative phytochemical analysis
In order to identify the chemical structure of the com-
pounds responsible for the antioxidant and anti-
atherosclerogenic activity, preliminary tests of the
phytochemical study were conducted following the
procedures described by Trease and Evans [18]. Briefly,
Essential oils from the aqueous extract of C. occidenta-
lis were extracted with hexane. These extracts were
then stitched onto plates of thin layer chromatography
on silica, the first disclosure was obtained by ultraviolet
radiation (254 nm and 365 nm) and then with vanillin.
Analytical tests for the identification of different fam-
ilies of metabolites in crude extracts of the leaves were
performed at the national Institute of Medicinal Plants
for Medicinal research (IMPM, Cameroon).
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Animals
Sixty normo-cholesterolemic (NC) male Wistar rats (178.35
± 1.46 g) were purchased from Yaounde (Cameroon)
Pasteur Institute and acclimated to the Laboratory of
Medicinal Plants, Health and Galenic Formulation of
the Department of Biological Sciences, University of
Ngaoundere (Cameroon). Animals were housed under
controlled room temperature (24 ± 2 °C) and had ad
libitum access to food [National Veterinary Laboratory
(LANAVET), Garoua, Cameroon] and tap water. Ani-
mals were monitored for signs of general toxicity,
under the supervision of a veterinarian. The number of
animal per group approved in the experiments by the
institutional committee of ethics was five. All experi-
mental procedures were approved by the institutional
Ethical committee of Department of Biological Science
of the university of Ngaoundéré (ECDBSUN 15/01/
2015/UN/FS/DSB).
Experimental procedures
Normo-cholesterolemic (NC) (60 rats) were divided into
6 groups of 10 rats. Five groups were fed for 4 weeks
with a diet consisting of 50% Corn Starch, 11.25% Rice
Powder, 01% vegetable oil, 10% egg white, 08% fish meal,
19% Cellulose, 0.125% mineral complex, 0.125% vitamin
Complex and 0.50% Salt [19, 20]. For induction of
hypercholesterolemia (HC), 1% of cholesterol was added
in the feed of rats. The nutrient contents of the NC (g/
100 g food) diet were: total lipid (19.70 ± 0.28); protein
(32.95 ± 2.4); ash (0.02 ± 0.005); fiber (12.33 ± 1.50); carbo-
hydrates (35 ± 2.3) [21]. The plant extract was adminis-
tered to animals at the increasing dose of 240, 320 and
400 mg/kg. After 4 weeks of treatment 5 rats out of 10
were sacrificed, blood samples, aorta, liver, and fresh faecal
were collected and processed for biochemical tests. The
remaining 5 rats were sacrificed 4 weeks after the end
treatment and blood were collected again for biochemical
analysis. Results were later compared to first group to
confirm the anti-atherogenic properties of the leaves
extract. Blood collected in heparinized tubes, were centri-
fuged at 3000 rev/min for 10 min; the supernatant
(plasma) was used for the enzymatic determination of
total cholesterol, HDL-c and triglycerides and malondial-
dehyde. Blood pellet was used in the preparation of hemo-
lysates while the portion of the liver collected was used to
prepare liver homogenates for the dosage of catalase,
hydroperoxides and proteins. The experiments were con-
ducted under the same conditions with Atorvastatin®
(1 mg/kg), as pharmacological reference substance.
Body temperature monitoring
Body temperature of treated rats was monitored daily 5 h
after treatment using a rat rectal thermometer. It was
inserted at a distance of approximately 2 mm in the anus.
Statistical analysis
Data obtained from the different experimental groups
were compared by one-way ANOVA followed by LSD
test for post hoc analysis, using Origin software (Origin
Lab, Northampton, MA, USA). Test groups were com-
pared to normal, disease, and positive control groups.
Differences with P < 0.05 were considered significant.
Data are presented as mean ± SEM.
Results
Body weight
During the 4 weeks period of induction, the body weight of
animals in the Normocholesterolemic fed with cholesterol-
free diet, significantly increased (P < 0.05) from 3.22% in
week one to 17.12% at week 4. Animals fed with a diet rich
in cholesterol, have seen their body weights increased sig-
nificantly (P < 0.05) to 5.11% in week 1 to 49.11% at week 4
(Fig. 1). During the four weeks of treatment extract-treated
animals showed a dose-dependent loss of body weight. Ani-
mals treated daily with a dose of 240 mg/kg of the extract
experienced a decreased in the relative body weight of
2.67% and 8.39% respectively in week 1 and week 4. with
the slope y = −3.14x + 264.6, r2 = 0.97. At a daily dose of
320 mg/kg y = −5.67x + 264.2, r2 = 0.95, and animals that
received the extract at a dose 400 mg/kg, have seen their
body weight decreased from 268.33 ± 0.82 g/rat to 247.66 ±
3.68 g/rat in week 1 and from 247.66 ± 3.68 g/rat to 199.77
± 3.87 g/rat in week 4, leading to a decrease of 8.34% and
34.31% respectively with the slope y = −9.83x + 271.1, r2 =
0.98 (Fig. 1). The increase in body weight observed in ani-
mals receiving Atorvastatin was also significant (P < 0.05)
(Fig. 1). A significant body weight gain was observed in
general in all the group of animals without any plant extract
treatment 4 weeks after (Fig. 1).
Water consumption and food intake
Average daily water and food intake are shown in Tables 1
and 2. During the treatment, the C. occidentalis extract
caused a significant increase (P < 0.01) in water consump-
tion and food intake. At a dose of 400 mg/kg, the increase
of drinking water was 29,89% and 49,88% respectively in
the first week and fourth week. Four weeks after treat-
ment, water consumption decreased in animals previously
treated with aqueous extract. At the dose of 400 mg/kg,
water consumption decreased by 60.61% and 180.77% re-
spectively in week 1 and week 4, when compared to the
water consumption during the treatment at the same dose
(Table 1). On the other hand, food intake also increased
comparably in all groups. HC + distilled water group
showed an increase of 44.66 ± 1.12% and 57.87 ± 1.23% re-
spectively in the 1st week and in the fourth week in food
consumption during treatment (y = 1.25x + 17.4, r2 = 0.99)
(Table 2). During the 4 weeks of hypercholesterolemia
treatment, food consumption significantly decreased
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(P < 0.05) in treated animals compared to HC+ distilled
water. At the dose of 400 mg/kg, there was a decrease in
food intake of 39.55 ± 1.33% in the first week and 23.68 ±
1.45% in week 4 compared to HC+H20 (y = 2.24x + 16.76,
r2 = 0.97). At a dose of 240 mg/kg (y = 3.45x + 13.56, r2 =
0.99), 320 mg/kg (y = 2.32x + 18.83, r2 = 0.99), and Atorva-
statin (y = 1.69x + 19.14, r2 = 0.93)] (Table 2).
Organ weight
After 4 weeks of treatment of hypercholesterolemia, the
Organ weight including the liver, kidney, heart and the
testis of animals received extract at doses (240, 320 and
400 mg/kg) compared with the group hypercholesterol-
emic untreated and groups normocholesterolemic did
not present any significant change ( < 0.05) (Table 3).
Body temperature
No significant change was observed in the body temperature
in treated animals compared to Hypercholesterolemic +
distilled water and atorvastatin; or after inter-group
comparisons, during the treatment period (Table 4) and
4 weeks after (data not shown). Effects of aqueous extract
leaves of C. occidentalis on body temperature measured
daily 5-h after treatment are presented in Table 4.
Effect of aqueous extract of C. occidentalis on blood
lipid parameters
During treatment
Rat treated with extract showed a significant reduction
and dose-dependent of TC level. TC decreased from
156.09 ± 0.92 mg/dl to 135.51 ± 0.51 mg/dl, at a dose of
240 mg/kg, 116.63 ± 0.54 mg/dl at a dose of 320 mg/kg,
and 106.07 ± 0.69 mg/dl at a dose of 400 mg/kg, leading
to a decrease of 13.18%, 25.28% and 32.05% respectively.
TC also decreased in the group which received a treat-
ment compared to the normocholesterolemic (Table 5).
TG decreased from from 141.01 ± 0.63 mg/dl to
101.62 ± 0.98 mg/dl leading to a decrease of 27.93%, 32.58%
and 39.62% respectively at a doses 240, 320 and 400 mg/kg
compared to the normocholesterolemic (Table 5).











HC + Distilled water 0 116.12 ± 1.21 137.12 ± 1.12 142.10 ± 1.22 146.21 ± 1.32
During treatment HC + Extract 240 179.04 ± 1.23*a 158.32 ± 1.16*a 160.24 ± 1.14*a 179.31 ± 1.22*a
320 139.43 ± 1.22**a 200.31 ± 1.32**a 215.12 ± 1.32**a 236.83 ± 1.11**a
400 178.43 ± 2.33**a 239.25 ± 1.67**a 265.27 ± 2.37**a 289.66 ± 1.23**a
HC + Atorvastatin 1 145.95 ± 1.12 164.75 ± 1.13 174.15 ± 1.13 166.64 ± 1.12
After treatment HC + Extract 240 86.33 ± 1.17**b 88.44 ± 1.17**b 89.22 ± 1.17**b 89.10 ± .1.20**b
320 95.32 ± 1.66**b 86.22 ± 1.16**b 97.12 ± 1.77**b 98.44 ± 1.25**b
400 103.93 ± 1.11**b 99.77 ± 1.11**b 100.93 ± 1.01**b 101.65 ± 0.83**b
HC + Atorvastatin 1 141.85 ± 3.72 162.75 ± 2.76 160.75 ± 3.78 166.69 ± 1.03
Values are means ± S.E.M., n = 5, *P < 0.05, **P < 0.01 significant difference compared to HC+ Distilled water. HC Hypercholesterolemic rat; asignificant difference
compared to HC+ Distilled water; bsignificant difference compared to animals previously treated with aqueous extract during the treatment at the same dose
Fig. 1 variation of the body weight of the rats per week. Values are represented as mean ± standard error of mean, n = 5. dH2O: distilled water.
HC: Hypercholesterolemic rats; NC: Normocholesterolemic rats
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Table 4 also shows HDL-c rate during treatment. Rats
treated with Atorvastatin showed a significant decreased
of HDL-c level compared to the normocholesterolemic,
leading to a decrease of 3.33%. Rat treated with extract
showed a significant reduction and dose-dependent of
HDL-c levels, compared to the normocholesterolemic,
leading to a decrease of 13.33%, 6.66% and an increase of
13.33% respectively at the doses of 240, 320 and 400 mg/
kg compared to the normocholesterolemic (Table 5).
LDL-c rate decrease from 109.28 ± 0.49 mg/dL with
the normocholesterolemic to 53.02 ± 0.83 mg/dL for
the rats treated with Atorvastatin, and to 81.53 ±
0.5 mg/dL, 53.02 ± 0.83 mg/dL, 36.17 ± 0.34 mg/dL for
the rats treated with extract at the doses of 240, 320
and 400 mg/kg respectively compared to the normo-
cholesterolemic (Table 5).
VLDL-c levels decrease from 28.21 ± 0.73 with the
normocholesterolemic to 20.33 ± 0.79, 19.02 ± 0.66 and
16.65 ± 0.38, with the rats treated with extract with the
doses of 240, 320 and 400 mg/kg respectively compared
to the normocholesterolemic. Leading to a decrease of
27.93%, 32.57% and of 40.97% respectively at the doses
of 240, 320 and 400 mg/kg compared to the normocho-
lesterolemic (Table 5). Treatment with Atorvastatin,
showed a decrease of 38.78%.
Ratio of LDL/HDL-C and TC/HDL-c
In normocholesterolemic, the TC/HDL-c had a non-
significant increase (P > 0.05), whereas LDL/HDL-c also
showed no significant differences (P > 0.05). Hypercholes-
terolemic rat treated with Atorvastatin showed a 365.87%
reduction in LDL/HDL-c against 156.53% in TC/HDL-c
levels. Rats treated with the extract at the dose of 400 mg/
kg showed a reduction of LDL/HDL-c ratio of 511.45%
when compared to the Hypercholesterolemic + distilled
water rats. This reduction was also observed in the TC/
HDL-c and the value decreased from 8.44 ± 0.82 in Hyper-
cholesterolemic + distilled water rats to 3.96 ± 0.15 in rats
treated with the extract at dose of 400 mg/kg, equivalent
to a reduction of 113.13%. (Table 5). LDL/HDL-c ratio
decreased in a dose-dependent manner when compared
with Hypercholesterolemic + distilled water rats.
After treatment
The interest of this study consisted in checking that after
4 weeks of treatment, the extract would always act.the
aim would be to highlight vasodilators which can recon-
stitute the level of integrity of the endothelium and the
production and the diffusion of the oxide nitrite. Four
weeks after replacement of Hypercholesterolemic diet
with normal rat chow and concomitant end of treatments,










HC + Distilled water 0 44.66 ± 1.12% 54.12 ± 1.10% 55.11 ± 1.22% 57.87 ± 1.23%
During treatment HC + Extract 240 56.80 ± 1.12% 54.47 ± 1.14% 50.23 ± 1.24%*a 47.47 ± 1.32%**a
320 54.23 ± 1.45% 52.39 ± 1.09%*a 50.22 ± 1.19%*a 45.39 ± 1.23%**a
400 39.55 ± 1.33%*a 35.54 ± 1.32%*a 28.34 ± 1.12%**a 23.68 ± 1.45%**a
HC + Atorvastatin 1 36.17 ± 1.32%**a 37.16 ± 1.06%**a 39.37 ± 1.32%**a 43.41 ± 1.13%**a
After treatment HC + Extract 240 53.13 ± 1.56% 56.32 ± 1.21%*b 58.87 ± 1.22%*b 62.23 ± 1.12%**b
320 56.16 ± 1.32%*b 55.33 ± 1.41%*b 60.77 ± 1.42%*b 62.44 ± 1.54%**b
400 47.33 ± 1.22%*b 49.33 ± 1.25%**b 52.22 ± 1.32%**b 59.80 ± 1.11%**b
HC + Atorvastatin 1 39.21 ± 1.14%*b 41.89 ± 1.31%*b 45.82 ± 1.34%*b 49.15 ± 1.22%**b
Values are means ± S.E.M., n = 5, *P < 0.05, **P < 0.01, HC Hypercholesterolemic rat; asignificant difference compared to HC+ Distilled water; bsignificant difference
compared to animals previously treated with aqueous extract during the treatment at the same dose
Table 3 Effects of C. occidentalis extract administration for 4 weeks on organ weight
Group Organ weight
Liver Heart Kidney Testis
HC + dH2O 3.04 ± 0.71 0.34 ± 0.07 0.66 ± 0.35 0.55 ± 0.12
C. occidentalis treated 240 mg/kg 3.04 ± 0.15 0.33 ± 0.03 0.64 ± 0.07 0.53 ± 0.17
320 mg/kg 3.05 ± 0.91 0.32 ± 0.07 0.62 ± 0.53 0.53 ± 0.14
400 mg/kg 3.01 ± 0.25 0.32 ± 0.04 0.61 ± 0.04 0.53 ± 0.13
Atorvastatin (1 mg/kg) 3.02 ± 0.18 0.32 ± 0.07 0.61 ± 0.06 0.52 ± 0.16
NC 3.01 ± 0.26 0.30 ± 0.10 0.61 ± 0.25 0.52 ± 0.18
Values are represented as mean ± standard error of mean, n = 5. No significant change was observed. dH2O distilled water, HC Hypercholesterolemic rats,
NC Normocholesterolemic rats
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physiological levels of blood lipid parameters were still
observed in animals treated with either Atorvastatin or
a dose of extract (Table 5). Compared to those given
normal rat chow (normocholesterolemic rats), animals
given a diet enriched in cholesterol 4 weeks and only
distilled water (Hypercholesterolemic rats) showed sig-
nificant (P < 0.05) increases in total cholesterol (124.23%),
in triglycerides (103.01%), in very low density lipopro-
tein (VLDL-c) cholesterol (96.03%), in LDL cholesterol
(330.57%), and a decrease in HDL cholesterol (3.26%).
These alterations were prevented in Hypercholesterol-
emic rats treated with Atorvastatin, as expected, but
also by the three doses of extract in a dose-dependent
fashion (Table 5).
Ratio of LDL/HDL-c and TC/HDL-c
There were a significant changes in LDL/HDL-c and
TC/HDL-c ratios in rats, 4 weeks after treatment. LDL/
HDL-c ratio decreased from 5.87 ± 0.05 in Hypercholes-
terolemic + distilled water rats without diet consisting to
0.91 ± 0.02 in the rats treated with C. occidentalis at the
dose of 400 mg/kg after treatment. The TC/HDL-c also
decreased from 8.44 ± 0.82in Hypercholesterolemic + dis-
tilled water rats without diet consisting to 2.72 ± 0.12 in
the rats treated with C. occidentalis at the dose of 400 mg/
kg after treatment. (Table 7). The of LDL/HDL-c ratios
and TC/HDL-c ratios were significantly increased in Hy-
percholesterolemic rats (P < 0.05) compared to normocho-
lesterolemic rats (Table 4). Such alteration in these ratios
was prevented in Hypercholesterolemic rats by atorva-
statin treatment, but also by treatments with extracts of C.
occidentalis, in a dose-dependent fashion (Table 5).
Effect of the aqueous extract of C occidentalis on
oxidative stress markers in liver homogenates and blood
The effect of the aqueous extract of C. occidentalis on
various markers of oxidative stress markers in liver ho-
mogenates, hemolysates, and plasma was dose-dependent
as shown in (Table 6). Catalase activities in liver homog-
enates and in hemolysates were significantly decreased
(P < 0.05). The extract also induced a significant decrease
in hydroperoxide amount in liver homogenates (P <
0.001), and an increase in blood plasma (P < 0.05). Plasma
and liver malondialdehyde amounts were significantly
Table 4 Effect of C. occidentalis extract administration for 4 weeks on body temperature
Time
(days)
Extract of C. occidentalis (mg/kg) Atorvastatin
(1 mg/kg)Control 240 320 400
1 36.11 ± 0.13 36.12 ± 0.12 36.13 ± 0.11 37.13 ± 0.13 36.13 ± 0.13
2 36.12 ± 0.12 36.13 ± 0.15 37.14 ± 0.13 36.11 ± 0.14 36.12 ± 0.13
3 37.13 ± 0.12 36.13 ± 0.11 35.15 ± 0.11 36.13 ± 0.13 37.14 ± 0.11
4 36.12 ± 0.15 36.14 ± 0.12 37.12 ± 0.12 36.12 ± 0.12 36.11 ± 0.13
5 36.13 ± 0.11 36.11 ± 0.13 36.14 ± 0.13 36.12 ± 0.14 36.12 ± 0.11
6 36.14 ± 0.13 36.14 ± 0.13 36.12 ± 0.12 36.13 ± 0.11 36.13 ± 0.11
7 36.11 ± 0.12 36.12 ± 0.14 36.13 ± 0.13 37.12 ± 0.13 36.13 ± 0.13
30 37.09 ± 0.14 36.14 ± 0.12 36.14 ± 0.14 36.12 ± 0.11 36.12 ± 0.14
Values are represented as mean ± standard error of mean, n = 5. No significant change was observed
dH2O distilled water
Table 5 Effect of aqueous extract of C. occidentalis on blood lipid parameters
Experimental groups Lipid parameters (mg/dL)
TC TG VLDL-c HDL-c LDL-c LDL/HDL CT/HDL
HC rats + dH2O 156.09 ± 0.92 141.01 ± 0.63 28.21 ± 0.73 31.05 ± 0.48* 109.28 ± 0.49 5.87 ± 0.05 8.44 ± 0.82
HC +4 weeks
treatment
240 mg/kg 135.51 ± 0.51* 101.62 ± 0.98* 20.33 ± 0.79* 26.73 ± 0.47 81.53 ± 0.5* 3.05 ± 0.07* 6.25 ± 0.34*
320 mg/kg 116.63 ± 0,54* 95.06 ± 0.57* 19.02 ± 0.66* 28.35 ± 0.58* 53.02 ± 0.83* 1.87 ± 0.06* 4.59 ± 0.16*
400 mg/kg 106.07 ± 0.69* 85.15 ± 0.64* 16.65 ± 0.38* 34.77 ± 0.6* 36.17 ± 0.34* 0.96 ± 0.04* 3.96 ± 0.15*
HC 4 weeks after
treatment
240 mg/kg 130.12 ± 0.11* 98.13 ± 0.30* 18.30 ± 0.70* 27.12 ± 0.17 80.31 ± 0.15* 2.96 ± 0.02* 4.79 ± 0.13*
320 mg/kg 110.22 ± 0,34* 89.16 ± 0.33* 16.12 ± 0.25* 30.22 ± 0.32* 48.22 ± 0.23* 1.59 ± 0.03* 3.64 ± 0.11*
400 mg/kg 99.14 ± 0.44* 79.17 ± 0.24* 14.25 ± 0.31* 36.43 ± 0.21* 33.27 ± 0.14* 0.91 ± 0.02* 2.72 ± 0.12*
HC + Atorvastatin 1 mg/kg 95.23 ± 0.57* 86.84 ± 0.84* 17.27 ± 0.63* 31.05 ± 0.48* 39.06 ± 0.97* 1.26 ± 0.04* 3.29 ± 0.42*
NC rats 69.61 ± 0.92 69.46 ± 0.58 14.39 ± 0.57 30.83 ± 0.39 25.38 ± 0.66 0.83 ± 0.07 2.28 ± 0.07
Data are represented as mean ± standard error of mean, n = 5. One-way ANOVA + LSD test against hypercholesterolemic (HC) rats: *P < 0.05. dH2O distilled water,
HDL-c high density lipoprotein cholesterol, LDL-c low density lipoprotein cholesterol, NC normocholesterolemic, T treatment, TC total cholesterol, TG triglyceride,
VLDL-c very low density lipoprotein cholesterol
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decreased (p < 0.05). Glutathione concentration in
plasma was decreased (P < 0.01). Protein amounts were
decreased in liver homogenates (P < 0.01) and increased
in hemolysates (P < 0.05). Protein level was decreased
in liver homogenates (y = −5.77x + 52.7, r2 = 0.93) and
increased in hemolysates (y = 3.42x + 44.8, r2 = 0.95) of
Hypercholesterolemic rats treated with the extract.
Changes in liver homogenates were significant at higher
doses of extract (P < 0.01), whereas Catalase level was
increased in the liver (y = 0.04x−0.03, r2 = 0.772) of
Hypercholesterolemic rats treated with the extract
(Table 6). Such increase was significant at the highest
dose tested (P < 0.05). Catalase level was also increased in
hemolysates of these animals (y = 0.05x−0.014, r2 = 0.84).
Malondialdehyde (MDA) level was decreased in the
liver (y = −0.77x + 11.19, r2 = 0.94) and in blood plasma
(y = −3.58x + 33.4, r2 = 0.96) of Hypercholesterolemic rats
treated with the extract (Table 5). These decreased were
significant at higher doses tested (P < 0.05). Hydroperoxide
(ROOH) level was decreased in the liver at the highest
dose tested (y = 0.02x + 0.03, r2 = 0.98, P < 0.05), and in
plasma (y = −0.19x + 1.7, r2 = 0.80) (Table 6).
Effect of the aqueous extract of C occidentalis on
bilirubin, fecal cholesterol and blood urea
C. occidentalis did not have any change on bilirubin
elimination from blood. evertheless, it is necessary to
note the lack of significant difference of bilirubin level
between rats treated with aqueous extract and the
untreated rats (Table 7). During the last 5 days of the
treatment, faecal cholesterol was evaluated. Faecal
cholesterol of rats treated with extract increased from
1.04 ± 0.27 mg/dl to 11.47 ± 0.75, 14.11 ± 1.63, 15.04 ±
1.98 mg/dl respectively at the doses of 240, 320,
400 mg/kg. Rats treated with atorvastatin showed an
increase rate of fecal cholesterol of 1434.61% compared
to the normocholesterolemic. Table 7 shows the blood
urea level after treatment. It is deduced from this table
that; there is no significant difference in the level of
urea present in the blood of rats treated with aqueous
extract and the untreated rats (Table 7).
Phytochemical study
Phytochemical screening performed on crude extracts
revealed the presence of several primary and secondary
metabolites such as fatty acids, anthraquinones, glyco-
sides, anthracenes, saponins, tannins, and coumarins.
Phenolic compounds, triterpenes, volatile oils and ste-
rols, but also flavonoids and alkaloids were also present
in the extract. Thin layer chromatography (TLC)
showed that the hexane extract and urine of treated
rats contained four chemical fractions. These initial ob-
servations and findings suggest that the aqueous extract
of leaves of C. occidentalis contains several chemical
compounds with potential biological activities which
deserve further investigation.















Liver homogenates dH2O 10.77 ± 1.44 1.28 ± 0.10 0.02 ± 0.13 54.11 ± 0.54 —
400 mg/kg extract 8.89 ± 1.77* 0.87 ± 0.15*** 0.19 ± 0.17* 29.33 ± 3.16** —
Blood plasma dH2O 19.67 ± 1.23 0.04 ± 0.11 — — 0.44 ± 0,056
400 mg/kg extract 7.13 ± 1.44*** 0.07 ± 0.12* — — 0.23 ± 0,033**
Blood pellet hemolysates dH2O — — 0.01 ± 0.014 43.77 ± 4.21 —
400 mg/kg extract — — 0.14 ± 0.14*** 52.65 ± 0.43* —
CAT catalase, MDA malondialdehyde, ROOH hydroperoxide. Values are mean ± S.E.M., n = 5. ANOVA + LSD test vs. negative control: * P < 0.05, **P < 0.01, ***P < 0.001
Table 7 Effect of the aqueous extract of C occidentalis on bilirubin, Faecal cholesterol and blood urea
Experimental groups Parameters (mg/dL)
Bilirubin Urea Creatinin Faecal cholesterol
HC rats + dH2O 0,87 ± 0,18 0.47 ± 0.02 0.41 ± 0.02 5,58 ± 1,04
HC +4 weeks treatment 240 mg/kg 0,90 ± 0,12 0.31 ± 0.04* 0.26 ± 0.04* 11,47 ± 0,75*
320 mg/kg 0,89 ± 0,14 0.28 ± 0.05* 0.24 ± 0.05* 14,11 ± 1,6*
400 mg/kg 0,91 ± 0,15 0.26 ± 0.03* 0.22 ± 0.03* 15,04 ± 1,98*
HC + Atorvastatin 1 mg/kg 0,92 ± 0,11 0.27 ± 0.03 0.28 ± 0.03* 15,96 ± 1,64*
NC rats 0,94 ± 0,13 0.35 ± 0.03 0.25 ± 0.03 1,04 ± 0,27
Data are represented as mean ± standard error of mean, n = 5. One-way ANOVA + LSD test against dH2O: distilled rats: *P < 0.05
HC Hypercholesterolemic rats, NC Normo-cholesterolemic rats
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Discussion
The aqueous extract of C. occidentalis reduced dose de-
pendently and significantly the triglyceride and cholesterol
levels in the rats. Ajayi et al. [22], reported that drugs with
anticholesteremic properties are also antioxidant. This
suggests aqueous extract of C. occidentalis may have anti-
oxidant properties. This property could justify the use of
the maceration of C. occidentalis in traditional medicine
to treat hypertension and to reduce the triglyceride and
cholesterol levels in blood [23, 24]. In our experiment, ani-
mal body weights were significantly increased compared
to the controls. This increase could have resulted in the
increase in the food and water intakes of the rats. Physio-
logically, the increase in the appetite could be due to orex-
ine, the stimulative hormone of appetite (Balkan, 2002).
Animals fed with a feeding diet rich in cholesterol, have
seen their body weights increased significantly, thus devel-
oped obesity [25, 26]. This increase in body weight is due
to the increase of fat tissue deposit much more on the
level of the hip. We also noted that body weight in rat fed
with HC + dH2O is significantly increasing in rat fed with
NC before treatment in Fig. 1. This result means that the
well nourished animals can take weight if they are in good
health. But what we noted, it is with the difference of 1%
of cholesterol giving in HC + dH2O, the Body weight in
rat fed with HC + dH2O is significantly increasing than
NC rat. We know that cholesterol induces the hormone
synthesis such as cortisol, the aldosteron, the testosteron
and the oestrogens which are the sex hormones may be
the increasing in cholesterol in the HC + dH2O rats would
have contributed to increase the rate of these hormones
and induce significantly increasing of body weight in rat
fed with HC + dH2O.
The treatment with the aqueous extract of C. occidenta-
lis, in the rat fed with a diet rich in cholesterol and trigly-
ceride compared with the untreated rat and normal rats,
induced a reduction in the contents of VLDL-c. This re-
duction of cholesterol is found on the level of the TC, the
LDL-c and Triglycerides. These results are similar with
those of several works completed with other plant ex-
tracts, such as the aqueous extract of Dunaliella salina
[27] and the ethanolic extract of Crataegus pinnatifida
[28], in rats subjected to a feeding regime enriched with
lipids. Considering that abnormal lipid profiles constitut-
ing the hallmark of HC-induced metabolic syndrome were
also prevented in the liver by the extract concomitantly
with a marked increase in total cholesterol excreted, we
hypothesized that hypolipidemic activity of the extract
may be mediated by reducing or inhibiting intestinal chol-
esterol absorption and increasing reverse cholesterol
transport, as observed with agents inducing comparable
hypolipidemic effects together with antioxidant effects
such as Ezetimibe [29, 30] and bile acid sequestering
cholestyramine [22, 31]. This reduction did not reach
the normal rate after 4 weeks of treatment and the 4
weeks without treatment what allow us to say that the
treatment during 4 weeks could be insufficient, but we
noticed a reduction in the rate of VLDL-c during the 4
weeks without treatment, it could be that the extract of
C. occidentalis continued to react and to show the effect-
iveness of the aqueous extract leaves. This effective
action could be explained by the presence of the various
chemical families present in the aqueous extract leaves.
we limited our research to the treatment in 4 weeks
without any time to reassure our self if after the treat-
ment the formation of the atherom could continue and
that the endothelium could find its integrity. The inter-
est of this study consisted in checking that after 4 weeks
of treatment, the extract would always act.the aim would
be to highlight vasodilators which can reconstitute the
level of integrity of the endothelium and the production
and the diffusion of the oxide nitrite. The ratios TC/
HDL and HDL/LDL are indexes of the coronary risk
[32]. The ratios of atherogenicity TC/HDL and HDL/
LDL of dyslipidemic rats treated with the extract of C.
occidentalis were significantly reduced. These results
reflect a lipidic profile antiatherogenic, and let suggest a
protective effect of the extract with respect to the
hypercholesterolemy induced by the mode enriched out
of cholesterol. At the rats hyperlipidemic, saponins,
steroid; especially saponins derived from the spirosta-
nol, seem to be responsible for the reduction in total
cholesterol. It was noted in all the cases a reduction in
LDL-c and sometimes an increase in HDL-c. Saponins
would act by formation of a complex with cholesterol
or would have a direct effect on the metabolism of
cholesterol. Several possible mechanisms of exercise-
induced atheroprotective effects have been proposed
such as increased HDL-c, decreased TC, and decreased
oxidized LDL-c levels [33]. In the present study, endur-
ance exercise and/or switching from the high fat to the
normal diet improved lipid profiles by lowering the
atherogenic plasma levels of total and LDL-c. However,
the marked change in lipid profile observed concerned
the plasma levels of the anti-atherogenic HDL-c. They
were significantly increased in the exercise trained
groups of rat (independently of the diet used) and not
in the sedentary rats which were switched from the
high fat to the control diet. Consequently, the athero-
genic index was less in the exercise trained than in the
rats with modified diet. Concerning plasma triglycerides,
studies have also shown that they are strongly correlated
with the prevalence and incidence of metabolic syndrome
and cardiovascular diseases [34].
Many experimental studies showed the effectiveness of
the medicinal plants or their extracts in the improvement
of the activities of the enzymes implied in the metabolism
of cholesterol [35]. Li et al. [36] showed that the increase
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in the activity of the Lecithin: Cholesterol Acyltransferase
Activity (LCAT) and probably the reduction in that of
hydroxy-methyl-glutary-coenzyme A reductase (HMG-
CoA reductase), both ensuring the homeostasis of chol-
esterol, could be regarded as persons in charge for the
reduction in the cholesterolemy, in the rat subjected to a
feeding regime enriched with cholesterol treated with
5% by the extract by Coriandrum sativum during 75 days
[36]. Moreover, Sudhop et al. [37] noted a rise in the
activity of the LCAT and an inhibition of HMG-CoA
reductase, in the rat made hypercholesterolemic treated
with 500 mg/kg of an extract leaves of Symplocos
cochinchinensis, during 28 days [38]. For this reason C.
occidentalis could have an effect in the increase of the
activity of the LCAT and in the reduction of hydroxy-
methyl-glutary-coenzyme A reductase. it is very difficult
to make a difference between efficacy of C. occidentalis
with the efficacy of other plant extract without know-
ledge in the content of each plant extract. For the mo-
ment we explore the ways that C. occidentalis act and
tried to explain the effect of the extract.
Our results showed in this model of hypercholesterol-
emy that several biomarkers of the oxydative stress faded
in the rats subjected to the diet rich in cholesterol. The
reduced glutathion is the most abundant endogenous
antioxydant which interacts with activated oxygenated
species, thus preventing the oxidation of the organic
substrates (proteins, ADN, fatty acids). It is used as sub-
strate of the glutathion peroxidase. The glutathion is also
a trapper of radicals superoxydes and it protects the
thiol groups from proteins against oxidation [39]. Our
results showed a reduction in glutathione levels in the
blood of the hypercholesterolemic rats. The determin-
ation of the specific activity of the superoxyde dismutase
(SOD), enzyme which catalyses the dismutation of the
anion superoxyde (O2
−) out of water and hydrogen per-
oxide [40]. Faraci and Didion [40] revealed a decrease of
the activity of the SOD in blood of the hypercholesterol-
emic rats. In response to the oxydative stress, the SOD
is controlled in two different ways. In the event of
moderate oxydative stress one observes a sur-expression
of the SOD. If the oxydative stress persists the SOD is
destroyed and its expression decreases. Paradoxically, an
excessive concentration of the SOD can be dangerous
because, in this case, it is the base of a hydrogen perox-
ide overproduction [41], would be secondary with the
increase in the production of O2
− [42]., Malondialdehyde
(MDA) is used as index of the lipidic peroxidation
resulting from the reaction of the active species oxygen-
ated with the membrane fatty acids [43]. In this study,
the levels of MDA in blood was significantly increased
in hypercholesterolemic rats. In treated group, the
aqueous extract of C. occidentalis substantially prevented
the decrease of GSH and the increase of MDA levels.
The treatment also reduced the activity of the SOD.
The polyphenols present in the aqueous extract of C.
occidentalis [44], could also explain the antioxidant
activity of this aqueous extract.
Gupta et al. [45], revealed that; treatment of rats with
aqueous extract of Annona squamosa induced a decrease
of VLDL-c, LDL, TG levels at the serum and liver and
activity of HMG-CoA reductase. Moreover, this extract
increased the rate of HDL-c, the activity of the LCAT
and the synthesis of the biliary acids at the hepatic level,
which involves a rise in the faecal excretion of choles-
terol in rat subjected to a feeding regime enriched with
cholesterol (2%) during 75 days. In the current study, it
was observed a decrease in the TC, LDL-c, TG levels
after treatment with C. occidentalis aqueous extract.
However, the reduction of those parameters did not
reach the normal and could be explained by the short
treatment period (4 weeks).
The results of this study showed a significant increase in
the faecal excretion of cholesterol, in the rats dyslipidemic
or hyperlipidemic treated with aqueous extract of C. occi-
dentalis compared with the untreated rats, which suggest
an increase in the activity of the 7 α-hydroxylase, enzyme
implicated in the transformation of cholesterol into biliary
acids. These results are similar with those obtained with
hypercholesterolemic rats, treated with aqueous extract
of Globularia alpum, which observed an increase in the
synthesis of the biliary acids at the hepatic level and an
increase in faecal cholesterol [46].
The aqueous extract of C. occidentalis has an hypocho-
lesterolemia effect and could then act effectively against
the transport of cholesterol by the increase in the activity
of the LCAT, thus resulting in enrichment of the HDL-c
out of cholesterol esters.
Conclusion
This study provides evidence of antihypercholesterolemia
and hypotriglycemia effects of aqueous extract of C. occi-
dentalis. It reduces Low Density Lipoprotein cholesterols
(LDL-c), triglycerides (TG) and increasing High Density
Lipoprotein cholesterols (HDL-c) in rats subjected to a
feeding regime enriched with cholesterol. The diuretic
activity of this extract justifies its use for the treatment
of high blood pressure. However, toxicological studies
need to be undertaken to ensure the safety use of this
plant extract.
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